We are live on
!
Find out more
SAM
Sectoral Asset Management Portfolio holdings
AUM
$121M
1-Year Est. Return
73.47%
This Fund
S&P 500
This Quarter
Est. Return
+14.67%
1 Year Est. Return
+73.47%
3 Year Est. Return
+165.77%
5 Year Est. Return
+169.27%
10 Year Est. Return
+1,136.49%
AUM
$2.63B
AUM Growth
+$404M
(+18%)
Cap. Flow
+$126M
Cap. Flow
% of AUM
4.79%
Top 10 Holdings %
Top 10 Hldgs %
47.42%
Holding
84
New
20
Increased
43
Reduced
13
Closed
7
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$64.6M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
+$35.6M |
| 3 |
AGN
Allergan plc
AGN
|
+$33.5M |
| 4 |
ALDR
Alder Biopharmaceuticals
ALDR
|
+$26.6M |
| 5 |
Biogen
BIIB
|
+$23.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$76.2M |
| 2 |
NPSP
NPS PHARMACEUTICALS INC
NPSP
|
+$58.1M |
| 3 |
Amgen
AMGN
|
+$36.4M |
| 4 |
AGN
Allergan Inc
AGN
|
+$34.6M |
| 5 |
PTC Therapeutics
PTCT
|
+$23.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 90.54% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Biogen
BIIB
$30.4B
| $210M | 7.99% |
498,212
+58,784
| +13% | +$23.2M |
|
2
BioMarin Pharmaceuticals
BMRN
$11.5B
| $176M | 6.67% |
1,409,031
+155,788
| +12% | +$16.5M |
|
|
CELG
3
DELISTED
Celgene Corp
CELG
| $139M | 5.29% |
1,208,858
+74,600
| +7% | +$8.91M |
|
|
4
Gilead Sciences
GILD
$167B
| $130M | 4.92% |
1,320,507
+636,200
| +93% | +$64.6M |
|
5
Incyte
INCY
$23.4B
| $122M | 4.65% |
1,336,144
+3,330
| +0.2% | +$275K |
|
|
AGN
6
DELISTED
Allergan plc
AGN
| $111M | 4.23% |
374,407
+117,557
| +46% | +$33.5M |
|
|
7
Amgen
AMGN
$198B
| $106M | 4.03% |
663,575
-230,898
| -26% | -$36.4M |
|
8
Teva Pharmaceuticals
TEVA
$37.3B
| $103M | 3.93% |
1,660,583
+279,695
| +20% | +$16.3M |
|
9
Thermo Fisher Scientific
TMO
$198B
| $78.9M | 3% |
587,136
+66,450
| +13% | +$8.57M |
|
10
Viatris
VTRS
$20.1B
| $71.6M | 2.72% |
1,206,838
-312,530
| -21% | -$17.8M |
|
|
ALXN
11
DELISTED
Alexion Pharmaceuticals
ALXN
| $68.7M | 2.61% |
396,324
+10,700
| +3% | +$1.94M |
|
|
12
Vertex Pharmaceuticals
VRTX
$123B
| $60.1M | 2.28% |
509,600
+297,350
| +140% | +$35.6M |
|
|
SHPG
13
DELISTED
Shire pic
SHPG
| $59.5M | 2.26% |
248,859
+12,735
| +5% | +$2.93M |
|
|
FOLD
14
DELISTED
Amicus Therapeutics
FOLD
| $54.2M | 2.06% |
4,986,138
+220,640
| +5% | +$1.94M |
|
15
Halozyme
HALO
$9.23B
| $53.2M | 2.02% |
3,727,551
+3,200
| +0.1% | +$46.1K |
|
16
Dr. Reddy's Laboratories
RDY
$10.5B
| $53M | 2.01% |
4,644,810
+829,965
| +22% | +$8.8M |
|
17
Pfizer
PFE
$143B
| $51.9M | 1.97% |
1,572,628
+297,379
| +23% | +$9.45M |
|
|
KERX
18
DELISTED
Keryx Biopharmaceuticals Inc
KERX
| $48.7M | 1.85% |
3,825,256
+567,898
| +17% | +$7.3M |
|
|
ICPT
19
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $46.5M | 1.77% |
164,947
-16,900
| -9% | -$3.66M |
|
|
20
PTC Therapeutics
PTCT
$6.52B
| $45.8M | 1.74% |
753,141
-381,989
| -34% | -$23.3M |
|
|
SGEN
21
DELISTED
Seagen Inc. Common Stock
SGEN
| $44.6M | 1.69% |
1,260,275
+156,200
| +14% | +$5.33M |
|
22
Perrigo
PRGO
$1.48B
| $44.5M | 1.69% |
268,624
+36,556
| +16% | +$5.83M |
|
|
PTLA
23
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $44.1M | 1.68% |
1,162,730
+42,351
| +4% | +$1.45M |
|
|
MNK
24
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| $43.5M | 1.65% |
343,370
-57,294
| -14% | -$6.55M |
|
|
OMED
25
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
| $39.5M | 1.5% |
1,533,578
-64,715
| -4% | -$1.64M |
|
Similar funds
RIP
CCM
LFWA
FWA
CF
WIM
MW
AFC
Sectoral Asset Management's Q1 2015 Portfolio in Review
As of Q1 2015, Sectoral Asset Management held 84 positions worth $2.63B, up 18% from $2.23B the previous quarter. Its ten largest holdings account for 47% of the portfolio.
Sectoral Asset Management deployed $126M of net new capital in Q1 2015, opening 20 new positions and adding to 43 existing holdings. Its largest new stake was Tetraphase Pharmaceuticals, Inc.: 30,270 shares worth $22.2M.
By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 89% a quarter earlier.
On the sell side, the largest reduction was Amgen, an estimated $36.4M trimmed.
- Sectoral Asset Management's largest Q1 2015 buy was Tetraphase Pharmaceuticals, Inc.: 30,270 shares worth $22.2M.
- Sectoral Asset Management added most to Gilead Sciences in Q1 2015, an estimated $64.6M increase.
- Sectoral Asset Management's biggest Q1 2015 reduction was Amgen, cutting an estimated $36.4M.
- Sectoral Asset Management fully exited Regeneron Pharmaceuticals in Q1 2015, selling an estimated $76.2M.
- Sectoral Asset Management's ten largest holdings make up 47% of its $2.63B portfolio in Q1 2015.
- Sectoral Asset Management opened 20 new positions and closed 7 in Q1 2015.
- Sectoral Asset Management's portfolio value rose 18% quarter-over-quarter to $2.63B.
Based on Sectoral Asset Management's 13F filing for Q1 2015, filed 14 May 2015.